Protaphane HM Penfill, 100me/ml cartridges, 3ml, 5pcs

Composition

Active ingredient:

insulin-isophane (human genetically engineered);

Auxiliary substances:

zinc chloride;

glycerol (glycerol);

metacresol;

phenol;

sodium hydrophosphate dihydrate;

protamine sulfate;

sodium hydroxide and / or hydrochloric acid (for pH adjustment);

water for injection

Pharmacological action

Protaphane HM penfill has a hypoglycemic effect.

It interacts with a specific plasma membrane receptor and penetrates the cell, where it activates phosphorylation of cellular proteins, stimulates glycogen synthetase, pyruvate dehydrogenase, hexokinase, and inhibits adipose tissue lipase and lipoprotein lipase. In combination with a specific receptor, it facilitates the penetration of glucose into cells, enhances its absorption by tissues and promotes conversion to glycogen. Increases glycogen storage in the muscles, stimulates the synthesis of peptides.

The effect develops 1.5 hours after subcutaneous use, reaches a maximum in 4-12 hours and lasts 24 hours. Protaphane NM Penfill in insulin-dependent diabetes mellitus is used as basal insulin in combination with short — acting insulin, in non-insulin-dependent-both for monotherapy and in combination with fast-acting insulins.

Indications

Type I diabetes mellitus, type II diabetes mellitus (with resistance to sulfonylurea derivatives, intercurrent diseases, operations and in the postoperative period, during pregnancy).

Contraindications

Hypoglycemia, insulinoma.

Side effects

Hypoglycemic conditions, allergic reactions, lipodystrophy (with prolonged use).

Interaction

The hypoglycemic effect is enhanced by acetylsalicylic acid, alcohol, alpha – and beta-blockers, amphetamine, anabolic steroids, clofibrate, cyclophosphamide, fenfluramine, fluoxetine, ifosfamide, MAO inhibitors, methyldopa, tetracyclines, tritoqualin, triphosphamide, Chlorprothixen, diazoxide, diuretics (especially thiazides), glucocorticoids, heparin, hormonal contraceptives, isoniazid, lithium carbonate, nicotinic acid, phenothiazines, sympathomimetics, tricyclic antidepressants.

How to take, course of use and dosage

Subcutaneously. The drug is intended for subcutaneous use. Insulin suspensions should not be administered intravenously.

The dose of the drug is selected individually, taking into account the needs of the patient. Usually, the need for insulin is from 0.3 to 1 IU / kg / day. The daily requirement for insulin may be higher in patients with insulin resistance (for example, during puberty, as well as in obese patients), and lower in patients with residual endogenous insulin production.

Protaphane ® NM can be used either as monotherapy or in combination with fast-acting or short-acting insulin.

Protaphane ® NM is usually administered subcutaneously, in the thigh area. If it is convenient, then injections can also be made in the anterior abdominal wall, in the gluteal region or in the area of the deltoid muscle of the shoulder. When the drug is administered in the thigh area, it is more slowly absorbed than when administered in other areas. If the injection is made in a drawn-out skin fold, the risk of accidental intramuscular use of the drug is minimized.

The needle should remain under the skin for at least 6 seconds, which guarantees a full dose. It is necessary to constantly change the injection sites within the anatomical area to prevent the development of lipodystrophy.

Protaphane ® NM Penfill® is designed for use with Novo Nordisk insulin injection systems and NovoFine® or NovoTvist®needles. Follow the detailed recommendations for use and use of the drug.

Dose adjustment

Concomitant diseases, especially those that are infectious and accompanied by fever, usually increase the body’s need for insulin. Dose adjustment of the drug may also be required if the patient has concomitant diseases of the kidneys, liver, adrenal gland, pituitary gland or thyroid gland. The need for dose adjustment may also arise if the patient’s physical activity or usual diet changes. Dose adjustment may be necessary when transferring a patient from one type of insulin to another

Overdose

Symptoms:  development of hypoglycemia (cold sweat, palpitations, tremors, hunger, agitation, irritability, pallor, headache, drowsiness, lack of movement, impaired speech and vision, depression). Severe hypoglycaemia can lead to temporary or permanent brain damage, coma, and death.

Treatment:  sugar or glucose solution inside (if the patient is conscious), subcutaneous, intravenous or intravenous — glucagon or intravenous-glucose.

Product form

suspension for subcutaneous use

Storage conditions

Store in a dark place at a temperature of 2-8 °C (do not freeze). The used bottle should be stored at room temperature no higher than 30 °C for 6 weeks. Protect from heat and sunlight.

Shelf life

30 months

Active ingredient

Human genetically engineered insulin isophane

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection

Description

For pregnant women as prescribed by a doctor, For Nursing mothers as prescribed by a doctor, For Children as prescribed by a doctor, For adults as prescribed by a doctor

Indications

Type 1 Diabetes, Type 2 Diabetes